​

Forte Biosciences Stock (NASDAQ:FBRX)

ForecastOwnershipFinancialsChart
Forte Biosciences by TradingView

Previous Close

$12.54

52W Range

$4.11 - $28.68

50D Avg

$7.83

200D Avg

$10.24

Market Cap

$79.56M

Avg Vol (3M)

$48.01K

Beta

2.86

Div Yield

-

FBRX Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Apr 13, 2017

Website

FBRX Performance

FBRX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-36.60M$-32.49M$-13.90M
Net Income$-35.48M$-31.48M$-13.86M
EBITDA$-36.60M$-32.48M$-13.90M
Basic EPS$-12.17$-24.92$-19.96
Diluted EPS$-12.17$-24.92$-19.96

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 21May 11, 21 | 4:30 PM

Peer Comparison

TickerCompany
CCCCC4 Therapeutics, Inc.
ABVCABVC BioPharma, Inc.
HOWLWerewolf Therapeutics, Inc.
RZLTRezolute, Inc.
TPSTTempest Therapeutics, Inc.
CELCCelcuity Inc.
ERASErasca, Inc.
EWTXEdgewise Therapeutics, Inc.
KTTAPasithea Therapeutics Corp.
INDPIndaptus Therapeutics, Inc.